Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 11, 2025
- Pharmaceuticals
- R&D
Roche’s Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at SABCS)
TOKYO, December 11, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on December 10, including the latest data of giredestrant for estrogen receptor (ER)- positive early-stage breast cancer, presented at the San Antonio Breast Cancer Symposium (SABCS) 2025.
Please refer to the link below for details of the press release:
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp